Labetuzumab Govitecan

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) containing labetuzumab, a mildly reduced, anti-CEACAM5 humanized monoclonal antibody, conjugated to the potent campthotecin derivative and topoisomerase I inhibitor SN-38, with antineoplastic activity. The monoclonal antibody moiety of labetuzumab govitecan selectively binds to carcinoembryonic cell adhesion molecule 5 (CEACAM5), which is abundantly expressed on the surface of a majority of solid tumors. Upon internalization and proteolytic cleavage, SN-38, the active metabolite of irinotecan, inhibits the activity of topoisomerase I in the tumor cells, eventually inhibiting both DNA replication and transcription and leading to tumor cell apoptosis.

**Synonyms:** - ADC IMMU-130 - Antibody-Drug Conjugate IMMU-130 - LABETUZUMAB GOVITECAN - Labetuzumab-SN-38 Immunoconjugate IMMU-130 - hMN14-SN38